docetaxel anhydrous has been researched along with substance p in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (substance p) | Trials (substance p) | Recent Studies (post-2010) (substance p) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 17,289 | 277 | 2,010 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | substance p (IC50) |
|---|---|---|---|
| Substance-P receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Substance-K receptor | Rattus norvegicus (Norway rat) | 0.2 | |
| Substance-K receptor | Homo sapiens (human) | 0.2455 | |
| Substance-P receptor | Homo sapiens (human) | 0.0011 | |
| Neuromedin-K receptor | Homo sapiens (human) | 0.125 | |
| Substance-K receptor | Mesocricetus auratus (golden hamster) | 0.148 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demir, N; Erin, N; Kale, Ş; Köksoy, S; Korcum, AF; Tanrıöver, G | 1 |
1 other study(ies) available for docetaxel anhydrous and substance p
| Article | Year |
|---|---|
Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Docetaxel; Female; Mice; Mice, Inbred BALB C; Substance P; Taxoids; Treatment Outcome | 2015 |